Mirum Pharmaceuticals, Inc. Interest Payable, Current
Mirum Pharmaceuticals, Inc. (MIRM) had Interest Payable, Current of $527.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:InterestPayableCurrent · last filed 2026-08-05
- 2026-06-30: Interest Payable, Current $527.00K.
- 2026-03-31: Interest Payable, Current $5.27M.
- 2025-12-31: Interest Payable, Current $2.11M.
- 2025-09-30: Interest Payable, Current $5.27M.
| Period end | Interest Payable, Current |
|---|---|
| 2026-06-30 | $527.00K 10-Q · filed 2026-08-05 |
| 2026-03-31 | $5.27M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $2.11M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $5.27M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $2.11M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $5.27M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $2.11M 10-K · filed 2026-02-25 |
| 2024-09-30 | $5.27M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $2.11M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $5.27M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $2.11M 10-K · filed 2025-02-26 |
| 2023-09-30 | $5.76M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $2.60M 10-Q · filed 2023-08-07 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |